Trial Outcomes & Findings for Aerobic Exercise in Parkinson's Disease (NCT NCT03808675)

NCT ID: NCT03808675

Last Updated: 2026-03-12

Results Overview

Measures change in the severity of parkinsonism. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Motor section (Part III), measured in the "practically defined" OFF state (after overnight, \~12 hours, withdrawal of PD medications). It measures specific signs like rigidity, tremor, bradykinesia (slowness of movement), and gait abnormalities by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-132). Higher scores worse for individual data points. Lower value better for change score.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

57 participants

Primary outcome timeframe

Final Visit at 1 year - Baseline

Results posted on

2026-03-12

Participant Flow

Phone Screen (n= 186) \>\> Excluded (n= 96) * Not meeting criteria (n= 60) * Declined (n= 36) In-Person Screened \& consented (n= 90) Excluded (n=33) \- Not meeting criteria (n=33)

Enrolled \& Randomized (n=57)

Participant milestones

Participant milestones
Measure
Control
Participants randomized to usual care with PD specific health education
Aerobic
Participants randomized to aerobic exercise
Overall Study
STARTED
28
29
Overall Study
COMPLETED
26
27
Overall Study
NOT COMPLETED
2
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Control
Participants randomized to usual care with PD specific health education
Aerobic
Participants randomized to aerobic exercise
Overall Study
Physician Decision
2
1
Overall Study
Withdrawal by Subject
0
1

Baseline Characteristics

Aerobic Exercise in Parkinson's Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control
n=28 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=29 Participants
Participants randomized to aerobic exercise
Total
n=57 Participants
Total of all reporting groups
Race (NIH/OMB)
More than one race
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Age, Continuous
67.4 year
STANDARD_DEVIATION 8.2 • n=9 Participants
65.8 year
STANDARD_DEVIATION 6.9 • n=9 Participants
66.6 year
STANDARD_DEVIATION 7.5 • n=18 Participants
Sex: Female, Male
Female
8 Participants
n=9 Participants
7 Participants
n=9 Participants
15 Participants
n=18 Participants
Sex: Female, Male
Male
20 Participants
n=9 Participants
22 Participants
n=9 Participants
42 Participants
n=18 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Race (NIH/OMB)
Asian
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Race (NIH/OMB)
White
28 Participants
n=9 Participants
29 Participants
n=9 Participants
57 Participants
n=18 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
28 Participants
n=9 Participants
29 Participants
n=9 Participants
57 Participants
n=18 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants
0 Participants
n=9 Participants
0 Participants
n=18 Participants
Education
16.9 year
STANDARD_DEVIATION 3.4 • n=9 Participants
15.6 year
STANDARD_DEVIATION 2.5 • n=9 Participants
16.2 year
STANDARD_DEVIATION 3.1 • n=18 Participants
Hoehn-Yahr Stage
2 scores on a scale
n=9 Participants
2 scores on a scale
n=9 Participants
2 scores on a scale
n=18 Participants
Duration of PD
4.5 year
STANDARD_DEVIATION 3.6 • n=9 Participants
2.9 year
STANDARD_DEVIATION 3.1 • n=9 Participants
3.7 year
STANDARD_DEVIATION 3.4 • n=18 Participants
L-dopa Equivalent Daily Dose (LEDD)
573 mg/day
STANDARD_DEVIATION 478 • n=9 Participants
481 mg/day
STANDARD_DEVIATION 374 • n=9 Participants
526 mg/day
STANDARD_DEVIATION 427 • n=18 Participants
VO2max
22.3 mL/kg/min
STANDARD_DEVIATION 5.8 • n=9 Participants
22.9 mL/kg/min
STANDARD_DEVIATION 5.1 • n=9 Participants
22.6 mL/kg/min
STANDARD_DEVIATION 5.4 • n=18 Participants
2-Minute Walk Test
662 feet
STANDARD_DEVIATION 76 • n=9 Participants
639 feet
STANDARD_DEVIATION 73 • n=9 Participants
650 feet
STANDARD_DEVIATION 75 • n=18 Participants
MDS-UPDRS Part III Motor (OFF) score
19.5 score on scale
STANDARD_DEVIATION 9.9 • n=9 Participants
16.5 score on scale
STANDARD_DEVIATION 10.8 • n=9 Participants
18.0 score on scale
STANDARD_DEVIATION 10.4 • n=18 Participants
MDS-UPDRS Part I Non-motor EDL score
5.8 score on scale
STANDARD_DEVIATION 3.3 • n=9 Participants
7.0 score on scale
STANDARD_DEVIATION 5.8 • n=9 Participants
6.4 score on scale
STANDARD_DEVIATION 4.7 • n=18 Participants
MDS-UPDRS Part II Motor EDL
4.8 score on scale
STANDARD_DEVIATION 3.7 • n=9 Participants
4.9 score on scale
STANDARD_DEVIATION 3.7 • n=9 Participants
4.8 score on scale
STANDARD_DEVIATION 3.7 • n=18 Participants
MDS-UPDRS Part III Motor (ON) score
15.6 score on scale
STANDARD_DEVIATION 8.4 • n=9 Participants
13.4 score on scale
STANDARD_DEVIATION 7.9 • n=9 Participants
14.5 score on scale
STANDARD_DEVIATION 8.2 • n=18 Participants
MDS-UPDRS Total score
26.2 score on scale
STANDARD_DEVIATION 11.8 • n=9 Participants
25.4 score on scale
STANDARD_DEVIATION 12.1 • n=9 Participants
25.8 score on scale
STANDARD_DEVIATION 11.9 • n=18 Participants
MDS-UPDRS Part IV Total score
2.6 score on a scale
STANDARD_DEVIATION 2.4 • n=9 Participants
2.0 score on a scale
STANDARD_DEVIATION 2.1 • n=9 Participants
2.3 score on a scale
STANDARD_DEVIATION 2.2 • n=18 Participants
9-Hole Pegboard Dexterity Test (in the OFF state)
26.6 seconds
STANDARD_DEVIATION 5.1 • n=9 Participants
26.7 seconds
STANDARD_DEVIATION 8.7 • n=9 Participants
26.6 seconds
STANDARD_DEVIATION 7.1 • n=18 Participants
9-Hole Pegboard Dexterity Test (in the ON state)
24.7 seconds
STANDARD_DEVIATION 4.7 • n=9 Participants
24.3 seconds
STANDARD_DEVIATION 7.1 • n=9 Participants
24.5 seconds
STANDARD_DEVIATION 6.0 • n=18 Participants
Delayed Recall of Rey Auditory Verbal Learning Test (AVLT-Recall)
8.5 words
STANDARD_DEVIATION 3.1 • n=9 Participants
7.9 words
STANDARD_DEVIATION 3.7 • n=9 Participants
8.2 words
STANDARD_DEVIATION 3.4 • n=18 Participants
Flanker Inhibitory Control and Attention Test
92.1 normed score
STANDARD_DEVIATION 7.7 • n=9 Participants
89.9 normed score
STANDARD_DEVIATION 19.1 • n=9 Participants
91.0 normed score
STANDARD_DEVIATION 14.6 • n=18 Participants
Montreal Cognitive Assessment (MoCA)
24.8 score on continuous scale
STANDARD_DEVIATION 3.0 • n=9 Participants
24.4 score on continuous scale
STANDARD_DEVIATION 2.5 • n=9 Participants
24.6 score on continuous scale
STANDARD_DEVIATION 2.7 • n=18 Participants
Controlled Oral Word Association Test (COWA)
42.4 total count of correct words
STANDARD_DEVIATION 10.4 • n=9 Participants
35.1 total count of correct words
STANDARD_DEVIATION 10.7 • n=9 Participants
38.6 total count of correct words
STANDARD_DEVIATION 11.1 • n=18 Participants
Block Design Test (BLOCKS)
35.6 scores on a scale
STANDARD_DEVIATION 8.1 • n=9 Participants
36.8 scores on a scale
STANDARD_DEVIATION 7.4 • n=9 Participants
36.2 scores on a scale
STANDARD_DEVIATION 7.7 • n=18 Participants
Judgement of Line Orientation test (JLO)
24.4 score on test
STANDARD_DEVIATION 4.6 • n=9 Participants
25.4 score on test
STANDARD_DEVIATION 4.1 • n=9 Participants
24.9 score on test
STANDARD_DEVIATION 4.4 • n=18 Participants
Complex Figure Test -Copy (CFT-Copy)
27.2 score on test
STANDARD_DEVIATION 5.3 • n=9 Participants
28.1 score on test
STANDARD_DEVIATION 4.4 • n=9 Participants
27.7 score on test
STANDARD_DEVIATION 4.9 • n=18 Participants
Complex Figure Test-Recall (CFT-Recall)
13.5 score on test
STANDARD_DEVIATION 5.2 • n=9 Participants
14.4 score on test
STANDARD_DEVIATION 5.2 • n=9 Participants
13.9 score on test
STANDARD_DEVIATION 5.2 • n=18 Participants
Trail Making Test - A (TMT-A)
40.3 seconds
STANDARD_DEVIATION 15.3 • n=9 Participants
37.9 seconds
STANDARD_DEVIATION 24.2 • n=9 Participants
39.1 seconds
STANDARD_DEVIATION 20.2 • n=18 Participants
Trail Making Test - B (TMT-B)
82.6 seconds
STANDARD_DEVIATION 31.3 • n=9 Participants
85.9 seconds
STANDARD_DEVIATION 37.3 • n=9 Participants
84.3 seconds
STANDARD_DEVIATION 34.2 • n=18 Participants
Road Safety Error Count
24.4 Errors
STANDARD_DEVIATION 10.3 • n=9 Participants
26.0 Errors
STANDARD_DEVIATION 10.9 • n=9 Participants
25.2 Errors
STANDARD_DEVIATION 10.5 • n=18 Participants
Parkinson's Disease Questionnaire - 39 Summary Index
5.4 score on scale
STANDARD_DEVIATION 4.0 • n=9 Participants
7.5 score on scale
STANDARD_DEVIATION 6.5 • n=9 Participants
6.5 score on scale
STANDARD_DEVIATION 5.6 • n=18 Participants
Superior Longitudinal Fasciculus Radial Diffusivity (rD)
54.9 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.0 • n=9 Participants
55.2 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.0 • n=9 Participants
55.0 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.0 • n=18 Participants
Geriatric Depression Scale-15
0.79 score on test
STANDARD_DEVIATION 0.88 • n=9 Participants
1.03 score on test
STANDARD_DEVIATION 1.27 • n=9 Participants
0.91 score on test
STANDARD_DEVIATION 1.09 • n=18 Participants
Beck Anxiety Inventory (BAI)
1.82 score on scale
STANDARD_DEVIATION 2.70 • n=9 Participants
2.21 score on scale
STANDARD_DEVIATION 2.68 • n=9 Participants
2.02 score on scale
STANDARD_DEVIATION 2.69 • n=18 Participants
Fatigue Severity Scale (FSS)
1.51 score on scale
STANDARD_DEVIATION 0.66 • n=9 Participants
1.62 score on scale
STANDARD_DEVIATION 0.98 • n=9 Participants
1.57 score on scale
STANDARD_DEVIATION 0.84 • n=18 Participants
Putamen Radial Diffusivity (rD)
62.8 mm^2/sec * 10^-5
STANDARD_DEVIATION 2.6 • n=9 Participants
63.5 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.5 • n=9 Participants
63.2 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.1 • n=18 Participants
Cingulum Cingulate Radial Diffusivity (rD)
55.6 mm^2/sec * 10^-5
STANDARD_DEVIATION 5.1 • n=9 Participants
56.9 mm^2/sec * 10^-5
STANDARD_DEVIATION 4.0 • n=9 Participants
56.2 mm^2/sec * 10^-5
STANDARD_DEVIATION 4.6 • n=18 Participants
COGSTAT
367.6 T-score
STANDARD_DEVIATION 46.6 • n=9 Participants
366.3 T-score
STANDARD_DEVIATION 58.0 • n=9 Participants
367.0 T-score
STANDARD_DEVIATION 52.2 • n=18 Participants
Benton Visual Retention Test (BVRT)
6.4 score on test
STANDARD_DEVIATION 2.9 • n=9 Participants
6.2 score on test
STANDARD_DEVIATION 3.1 • n=9 Participants
6.3 score on test
STANDARD_DEVIATION 3.0 • n=18 Participants

PRIMARY outcome

Timeframe: Final Visit at 1 year - Baseline

Measures change in the severity of parkinsonism. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Motor section (Part III), measured in the "practically defined" OFF state (after overnight, \~12 hours, withdrawal of PD medications). It measures specific signs like rigidity, tremor, bradykinesia (slowness of movement), and gait abnormalities by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-132). Higher scores worse for individual data points. Lower value better for change score.

Outcome measures

Outcome measures
Measure
Control
n=27 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=26 Participants
Participants randomized to aerobic exercise
Change in MDS-UPDRS Part III Motor (OFF) Score
0.44 score on scale
Standard Deviation 8.46
-2.96 score on scale
Standard Deviation 8.31

PRIMARY outcome

Timeframe: Final visit at 1 year - Baseline

Measures change in the executive function domains of inhibitory control and attention. Uncorrected Standard Score of the NIH Toolbox Flanker Inhibitory Control and Attention Test. The Raw Score is based on number correct × average reaction time (accuracy \& speed composite). The Uncorrected Standard Score is based on age-normed raw score with mean = 100 and SD = 15. Score range 40-160 with interpretation below: ≥ 130 - Very Superior, 115-129 - Superior, 85-114 - Average, 70-84 - Below Average, \< 70 - Impaired / markedly low attention control. Higher scores better for individual data points. Higher value better for change score.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Flanker Task
-1.0 scores on a scale
Standard Deviation 5.8
3.6 scores on a scale
Standard Deviation 18.5

PRIMARY outcome

Timeframe: Final Visit at 1 year - Baseline

Number of safety errors made during an experimental real-world road drive test, scored by a certified driving instructor per criteria in the Iowa Department of Transportation's Drive Test Scoring Standards. Higher error count score worse. Lower scores better for change score.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Road Safety Error Count
-2.5 Errors
Standard Deviation 9.5
-3.9 Errors
Standard Deviation 10.7

PRIMARY outcome

Timeframe: Final Visit at 1 year - Baseline

Questionnaire regarding activities of daily living and ability within the last month. PDQ-39 has 8 domains: Mobility (10 items) → max = 40, Activities of daily living (6 items) → max = 24, Emotional well-being (6 items) → max = 24, Stigma (4 items) → max = 16, Social support (3 items) → max = 12, Cognitions (4 items) → max = 16, Communication (3 items) → max = 12, Bodily discomfort (3 items) → max = 12. Domain Score=(Sum of item scores/Maximum possible)\*100 . The main outcome measure is PDQ-39 Summary Index (PDQ-39 SI) is the mean of the 8 domain scores (range = 0 to 100). Higher scores at datapoints are worse. Lower change score is better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in the Parkinson's Disease Questionnaire-39 (PDQ-39) Score
1.04 score on scale
Standard Deviation 4.18
-0.11 score on scale
Standard Deviation 4.64

PRIMARY outcome

Timeframe: Final Visit at 1 year - Baseline

Population: DTI MRI was not available in all subjects.

Brain tissue integrity. Change in regional diffusion coefficient for radial diffusivity (rD) on DTI. Higher scores worse at individual data points. Lower scores better for change.

Outcome measures

Outcome measures
Measure
Control
n=19 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=22 Participants
Participants randomized to aerobic exercise
Change in Cingulum Cingulate Radial Diffusivity (rD)
-2.23 mm^2/sec * 10^-5
Standard Deviation 4.8
-1.16 mm^2/sec * 10^-5
Standard Deviation 4.10

PRIMARY outcome

Timeframe: Final Visit at 1 year - Baseline

Population: DTI MRI was not available in all completers.

Brain tissue integrity. Change in regional diffusion coefficient for radial diffusivity (rD) on DTI. Higher scores worse at individual data points. Lower scores better for change.

Outcome measures

Outcome measures
Measure
Control
n=19 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=22 Participants
Participants randomized to aerobic exercise
Change in Superior Longitudinal Fasciculus Radial Diffusivity (rD)
0.12 mm^2/sec * 10^-5
Standard Deviation 0.75
0.09 mm^2/sec * 10^-5
Standard Deviation 1.56

PRIMARY outcome

Timeframe: Final Visit at 1 year - Baseline

Population: DTI not available in all completers

Brain tissue integrity. Change in regional diffusion coefficient for radial diffusivity (rD) on DTI. Higher scores worse at individual data points. Lower scores better for change.

Outcome measures

Outcome measures
Measure
Control
n=19 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=22 Participants
Participants randomized to aerobic exercise
Change in Putamen Radial Diffusivity
-0.03 mm^2/sec * 10^-5
Standard Deviation 1.83
-1.01 mm^2/sec * 10^-5
Standard Deviation 1.98

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Non-Motor Experiences of Daily Living questionnaire (Part I). Part IA It measures complex behaviors (e.g., cognition, mood) by the rater based on patient/caregiver responses. Part IB asks patient/caregiver about various body functions. Each item is rated 0-4, and the score reflect the status of each item over the past week. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score of IA and IB is reported (range 0-52). Higher scores at data points worse. Lower change scores better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in MDS-UPDRS Non-motor Experiences of Daily Living Subscale (Part I) Score
0.15 score on scale
Standard Deviation 4.00
0.41 score on scale
Standard Deviation 5.56

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Motor function. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Motor Experiences of Daily Living questionnaire (Part II). It measures motor function based on patient/caregiver responses. Each item is rated 0-4, and the score reflect the status of each item over the past week. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-52). Higher scores worse at individual datapoints. Lower change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in MDS-UPDRS Motor Experiences of Daily Living Score (Part II)
1.15 score on scale
Standard Deviation 2.74
-0.04 score on scale
Standard Deviation 4.16

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Measures change in the severity of parkinsonism while antiparkinsonian medications are working. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Motor section (Part III), measured in the ON state. It measures specific signs like rigidity, tremor, bradykinesia (slowness of movement), and gait abnormalities by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-132). Higher scores worse for individual data points. Lower value better for change score.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in ON Period MDS-UPDRS Motor Examination Subscale Score (Part 3)
-1.88 score on scale
Standard Deviation 8.61
-1.41 score on scale
Standard Deviation 6.98

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Motor Fluctuations and Dyskinesia questionnaire. It measures duration, severity, and functional impact of dyskinesias and OFF periods by questionnaire administered by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-24). Higher scores worse at data points. Lower change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in MDS-UPDRS Dyskinesia and Motor Fluctuations (Part 4)
0.58 score on scale
Standard Deviation 2.35
0.67 score on scale
Standard Deviation 2.73

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

This is the simple addition of MDS-UPDRS Part I, II, and III (ON) total scores. This is a global measure of disease severity and encompasses motor and non-motor symptoms by subjective and objective measures. Higher scores at data points worse. Lower change scores better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Total MDS-UPDRS Score
-1.77 score on scale
Standard Deviation 12.13
-1.04 score on scale
Standard Deviation 9.77

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Motor function. Locomotion, endurance. Distance that a participant can walk in 2-minutes at their usual speed, a measure in NIH Toolbox Motor Battery. It is measured in the ON state. Higher data point and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in 2-Minute Walk Test
16.0 feet
Standard Deviation 60.3
19.0 feet
Standard Deviation 57.8

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

An assessment of fine motor dexterity. Participants are asked to place 9 pegs into a board with 9 holes, then remove them as quickly as possible, one hand at a time. Time to complete is reported. Part of NIH Toolbox Motor Battery. measured in the "practically defined" OFF state (after overnight, \~12 hours, withdrawal of PD medications). Higher time to complete is worse for individual data points. Lower value better for change score.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in 9-Hole Peg Board Test (OFF)
-0.47 seconds
Standard Deviation 3.48
1.24 seconds
Standard Deviation 3.50

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

An assessment of fine motor dexterity. Participants are asked to place 9 pegs into a board with 9 holes, then remove them as quickly as possible, one hand at a time. Time to complete is reported. Part of NIH Toolbox Motor Battery. measured in the ON state (when antiparkinsonian medications are working). Higher time to complete is worse for individual data points. Lower value better for change score.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in 9-Hole Peg Board Test of NIH Toolbox Motor Battery (ON)
-0.51 seconds
Standard Deviation 4.23
0.88 seconds
Standard Deviation 7.13

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

This is a brief cognitive screening test that measures various domains. Range 0-30. A score of 26 or over is considered to be normal. Higher score at data points and for change better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Montreal Cognitive Assessment (MOCA)
-0.42 score
Standard Deviation 2.97
0.19 score
Standard Deviation 2.75

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Composite measure of cognitive impairment (COGSTAT) by assigning standard T scores (mean=50, SD=10) to each of the seven tests from the neuropsychological assessment battery (COWA, CFT-Copy, CFT-Recall, AVLT-Recall, BVRT, BLOCKS, and TMT \[B-A\]). Higher scores better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in COGSTAT Score
7.1 T-score
Standard Deviation 35.3
11.4 T-score
Standard Deviation 24.3

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Number of words created for each letter (C, F, L) of the Controlled Oral Word Association Test over 60 seconds for each letter. A test of verbal fluency, probes executive function (initiation, self-monitoring, inhibition of repeats), language (lexical access, phonemic organization), attention and working memory domains. Average healthy adult produces 12-15 words per letter. Higher score at data points and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Controlled Oral Word Association Task (COWA)
0.96 total words
Standard Deviation 6.07
3.33 total words
Standard Deviation 7.09

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Total score of the completion of the Block Design test. This test evaluates the ability to analyze and synthesize abstract visual patterns, manipulate spatial information mentally, and coordinate visual-motor construction skills. Raw score is sum of all points based on accuracy and speed of reproducing 14 designs. (range=0-68) - higher score and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Block Design Test (BLOCKS)
0.62 scores on a scale
Standard Deviation 5.15
0.00 scores on a scale
Standard Deviation 6.75

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Judgement of Line Orientation test measures ability to perceive and match the angular relationships between line orientations. It is a visuospatial perception test. Raw score is sum of all correctly identified items (range 0-30). Higher score at data points and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Judgment of Line Orientation Test (JLO)
0.44 score on test
Standard Deviation 4.45
0.74 score on test
Standard Deviation 2.94

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Cognition. Memory. Number of words that can be recalled after at least 30-minutes after hearing the list. Higher scores at data points and change scores better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Delayed Recall of Rey Auditory Verbal Learning Test (AVLT-Recall)
0.00 score on test
Standard Deviation 2.98
0.08 score on test
Standard Deviation 2.77

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Ability to copy the Rey-Osterrieth Complex Figure. Measures visuospatial construction, perceptual organization, planning, and motor control. There are 18 distinct elements, each scored 0-2, with a range of total score 0-36. Higher score at data points and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Complex Figure Test -Copy (CFT-Copy)
1.31 score on test
Standard Deviation 4.98
1.09 score on test
Standard Deviation 4.55

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Ability to remember and draw the Rey-Osterrieth Complex Figure as accurately as possible after 30 minutes of copying it. It measures long-term visual memory and retention. There are 18 distinct elements, each scored 0-2, with a range of total score 0-36. Higher score at data points and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Complex Figure Test-Recall (CFT-Recall)
0.87 score on test
Standard Deviation 4.57
0.06 score on test
Standard Deviation 5.08

SECONDARY outcome

Timeframe: Final Visit at 1-year - Baseline

Test of visuospatial perception and memory. 10 geometric designs are shown to the participant. Each design is viewed for 10 seconds and then reproduced from memory. We are reporting error counts (range 0-10). Higher scores worse at data points. Lower change value better.

Outcome measures

Outcome measures
Measure
Control
n=27 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=26 Participants
Participants randomized to aerobic exercise
Change in Benton Visual Retention Test (BVRT)
-0.77 score on test
Standard Deviation 2.26
-0.04 score on test
Standard Deviation 3.84

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Test of processing speed, visual scanning. Time in seconds to connect numbers in ascending order. Higher time at data points worse. Lower change value better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Trail Making Test- A (TMT-A)
-5.3 seconds
Standard Deviation 19.0
-2.5 seconds
Standard Deviation 26.1

SECONDARY outcome

Timeframe: Final visit at 1-year - Baseline

Test of set-shifting, executive function, divided attention. Time to connect letters and numbers, alternating between numbers and letters, going in ascending order. Higher time worse. Lower change value better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Trail Making Test - B (TMT-B)
-2.4 seconds
Standard Deviation 45.5
0.7 seconds
Standard Deviation 25.1

SECONDARY outcome

Timeframe: Final Visit at 1-year - Baseline

Measure of executive control from motor speed. Calculated as (Trail Making Test B - Trail Making Test A). Higher scores at data points worse. Lower change scores better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Trail Making Test B-A (TMT B-A)
2.9 seconds
Standard Deviation 37.5
3.2 seconds
Standard Deviation 28.4

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Severity of depression. Higher scores worse. Range: 0-15

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change of Geriatric Depression Scale (GDS) Score
0.00 score on scale
Standard Deviation 0.85
0.04 score on scale
Standard Deviation 1.06

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

anxiety symptoms within the last week. 21-item self-report questionnaire each describing a common anxiety symptom (physical or cognitive). Item scores: 0 - Not at all, 1 - Mildly-it did not bother me much, 2 - Moderately-it was very unpleasant but I could bear it, 3 - Severely-I could barely stand it. Range 0-63. Higher scores worse at data points. Lower change value better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Beck Anxiety Inventory (BAI) Score
-0.15 score on scale
Standard Deviation 1.99
0.93 score on scale
Standard Deviation 3.34

SECONDARY outcome

Timeframe: Final Visit at 1 year - Baseline

Severity of fatigue. questions on symptoms of fatigue within the last week. Format: 9 statements such as "I am easily fatigued" rated on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). Total score = sum of all items / number of items answered (i.e., average of 9 items). Range: 1 - 7. Interpretation: 1-2=No or minimal fatigue, 3-4=Moderate fatigue, ≥ 5: Severe fatigue (commonly used clinical cutoff). Higher scores worse at data points. Lower change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in Fatigue Severity Scale (FSS)
-0.12 score on scale
Standard Deviation 5.25
1.37 score on scale
Standard Deviation 8.30

OTHER_PRE_SPECIFIED outcome

Timeframe: Final Visit at 1-year - Baseline

Measurement of aerobic fitness in the ON stage. VO2 max is the maximum amount of oxygen the body can use during intense exercise, serving as a key indicator of cardiovascular fitness and endurance. It is measured in milliliters of oxygen per kilogram of body weight per minute (mL/kg/min). Higher scores at data points and change score better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in VO2max on Cycle Ergometry
0.42 ml/kg/min
Standard Deviation 3.64
-0.30 ml/kg/min
Standard Deviation 3.03

OTHER_PRE_SPECIFIED outcome

Timeframe: Final visit at 1-year - Baseline

LEDD is a standardized measure used to compare the total dopaminergic medication load across different Parkinson's disease (PD) treatments. It converts various dopaminergic agents to a common reference - the amount equivalent to 100 mg of standard oral levodopa - allowing consistent comparison across studies and patients. Higher is worse at data points. Lower change value better.

Outcome measures

Outcome measures
Measure
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
Change in L-dopa Equivalent Daily Dose (LEDD)
7.8 mg/day
Standard Deviation 233.5
106.5 mg/day
Standard Deviation 172.0

Adverse Events

Control

Serious events: 3 serious events
Other events: 2 other events
Deaths: 0 deaths

Aerobic

Serious events: 3 serious events
Other events: 21 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Control
n=28 participants at risk
Participants randomized to usual care with PD specific health education
Aerobic
n=29 participants at risk
Participants randomized to aerobic exercise
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
0.00%
0/29 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Cardiac disorders
Pacemaker insertion
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
0.00%
0/29 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Infections and infestations
COVID-19
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
3.4%
1/29 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Cardiac disorders
Coronary artery bypass
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
0.00%
0/29 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Musculoskeletal and connective tissue disorders
Inguinal hernia repair
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
3.4%
1/29 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Hepatobiliary disorders
Cholecystectomy
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
3.4%
1/29 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.

Other adverse events

Other adverse events
Measure
Control
n=28 participants at risk
Participants randomized to usual care with PD specific health education
Aerobic
n=29 participants at risk
Participants randomized to aerobic exercise
Infections and infestations
COVID-19
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
24.1%
7/29 • Number of events 7 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Musculoskeletal and connective tissue disorders
Back pain
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Musculoskeletal and connective tissue disorders
Arthralgia
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Musculoskeletal and connective tissue disorders
Back Pain
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Musculoskeletal and connective tissue disorders
Pain in Extremity
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
Injury, poisoning and procedural complications
Fall
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
6.9%
2/29 • Number of events 2 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.

Additional Information

Ergun Uc, MD

Iowa City VA Health Care System/University of Iowa Health Care

Phone: 319-356-1616

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place